Fig. 6: PSPH expression for the prediction of immunotherapy responses in GBM patients.
A The graphs show the Kaplan-Meier curve comparing the overall survival of GBM patients, equally divided in high versus low 50% PSPH expression using the GBM dataset n = 34 [107] of patients that were treated with anti-PD1. P value was calculated using a Log-rank Mantel–Cox test. B The graph shows the Kaplan-Meier curve comparing the overall survival equally divided in high versus low (50%) LGALS1 (Galectin-1) expression. P value was calculated using a Log-rank Mantel–Cox test. C Pearson correlation of LGALS1 and PSPH expression in patients with GBM (PIMD: 30996326). D Immunoblot analysis of the immunosuppressive protein Galectin-1 expression in 1919 GBM isogenic models with overexpression of PSPH and PSPHV116I in n ≥ 3 biological replicates and n = 3 technical repeats. One-way ANOVA with Dunnett’s multiple comparisons test has been performed. E Immunoblot analysis of the immunosuppressive protein Galectin-1 expression in 1919 GBM isogenic models with overexpression of PSPH and PSPHV116I. Cells were treated with DMSO as a control and 7.5 µM sertraline for 48 h. The graph shows the protein quantification corrected by the loading control lamin A and relative to the 1919 GFP Ctrl cells treated with DMSO in n = 3 biological replicates and n = 2 technical replicates. A one-way ANOVA with Šídák’s multiple comparisons test, comparing the GFP Ctrl cells treated with DMSO to the PSPHamp and PSPHV116I DMSO-treated cells, as well as comparing each cell model with their respective sertraline-treated groups. Statistical significance p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).
